UnitedHealth Group Inc. and Amedisys Inc. are preparing for a pivotal meeting next week with top officials from the Department of Justice (DOJ) as part of their efforts to secure approval for their proposed $3.3 billion merger. This high-stakes encounter, described by sources as a “last-rites” meeting, will involve discussions with Assistant Attorney General for Antitrust, Jonathan Kanter, among other key officials, according to Bloomberg.
As the companies approach this critical juncture, sources familiar with the negotiations indicate that the meeting could take place as early as Monday. The discussions come after more than a year of scrutiny by the DOJ, which has raised concerns that the merger could potentially lead to increased prices for home-health services. Per Bloomberg, the DOJ has until the end of October to make a formal decision regarding the merger, a timeline established under an agreement with the involved parties.
While no definitive decision has been reached, officials could permit the acquisition to move forward, potentially with conditions aimed at addressing competitive concerns. According to sources, to mitigate these worries, UnitedHealth and Amedisys have proposed divesting an undisclosed number of clinics to VCG Luna LLC, a subsidiary of Texas-based VitalCaring Group. This proposed solution has been under examination by the DOJ for several months following a comprehensive investigation initiated in August 2023.
Related: CVS and UnitedHealth Demand FTC Chair Recuse Herself from Insulin Price Suit
UnitedHealth, which has established itself as the largest health-services company in the U.S. by revenue through a series of strategic mergers that combine insurance with healthcare practices, is facing increased scrutiny from antitrust regulators. The DOJ is already investigating allegations regarding UnitedHealth’s monopolistic practices in various healthcare markets.
This merger is not UnitedHealth’s first venture into the home health sector; the company acquired LHC Group last year, a move that drew the attention of the Federal Trade Commission (FTC). The FTC ultimately did not challenge that deal since UnitedHealth was not actively competing in the home healthcare arena at that time. The LHC Group, which has nearly 1,000 locations across 37 states, combined with Amedisys’s 537 care centers operating in the same number of states, raises concerns about overlapping services, particularly in the South, where the merged entity would control a significant share of the market.
Despite the complexities surrounding the deal, both UnitedHealth and Amedisys have expressed their intentions to finalize the merger by the end of December. Meanwhile, neither company, nor the DOJ, has publicly commented on the pending meeting or the broader implications of the merger.
Source: Bloomberg
Featured News
EU and China to Continue Technical Negotiations on Electric Vehicle Tariffs
Oct 27, 2024 by
CPI
Pork Industry Giants Cite DOJ Letter to Bolster Defense Against Antitrust Claims
Oct 27, 2024 by
CPI
Paris Court Orders Google to Pay €26.5 Million to Equativ in Advertising Dispute
Oct 27, 2024 by
CPI
EU Fines Czech, Austrian Rail Operators €48.7M for Market Collusion
Oct 27, 2024 by
CPI
UnitedHealth and Amedisys Prepare for Key Antitrust Meeting with DOJ
Oct 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Chevron
Oct 24, 2024 by
CPI
A Quartet of Decisions That Cripple Agencies
Oct 24, 2024 by
Richard J. Pierce
Goodbye, Chevron: Rediscovering the Virtues of an Independent Judiciary
Oct 24, 2024 by
Alexander Volokh
A New Era of Deference: From Chevron to Loper Bright
Oct 24, 2024 by
Daniel E. Walters
Loper Bright and Antitrust: Limited Impact on Enforcement, but a Clear Constraint on FTC Rulemaking
Oct 24, 2024 by
David Kully, Lynn Calkins & Kenneth Racowski